Anand Padmanabhan MD, PhD
President & Chief Science Officer
Dr. Anand Padmanabhan, MD PhD is a Laboratory Medicine and Transfusion Medicine/Apheresis-trained physician at the BloodCenter of Wisconsin in Milwaukee. He received his medical degree from Thanjavur Medical College (India), PhD in Biochemistry from Brown University, and trained in leading programs in Laboratory Medicine (College of Physicians and Surgeons of Columbia University) and Transfusion Medicine/Apheresis (University of Pittsburgh Medical Center) before joining BloodCenter of Wisconsin in 2010. He is funded by the NIH to study Heparin induced Thrombocytopenia and thrombosis (HIT), a major cause of morbidity (30% thrombosis rate) and mortality (10%) in heparin-treated patients. Dr. Padmanabhan's interests include HIT epidemiology, pathogenesis, diagnosis and treatment and he has published in these areas in leading journals such as Blood, Chest and Lancet Haematology. He is lead inventor of technology that uses PF4-treated platelets to facilitate HIT diagnosis.
PhD, MBA, JD
CEO & General Counsel
Dr. Sem is also Dean and Professor of Business, Professor of Pharmaceutical Sciences and Director of Technology Transfer at Concordia University Wisconsin. He also serves on the editorial board of PLoS One Life Sciences, the Boards of Directors for the BBB and for Ozaukee County Economic Development Corp. Dr. Sem has over 20 years of experience in drug discovery and development, and has over 60 papers and 10 issued patents. He co-founded two drug discovery and development companies (Triad and AviMed) and one social venture (Bridge to Cures) before Retham. He served as VP for Biophysics at Triad Therapeutics, where he developed a platform technology for designing focused combinatorial libraries targeting kinases and dehydrogenases. He co-founded Triad Therapeutics based on technology he developed and patented, and he assisted in securing two rounds of venture financing, totaling over $40 million. Triad was voted one of the top 10 biotech startups in the U.S. in 2001 by Drug Discovery Today, and licensed kinase drug leads to Novartis for up to $60 million. Dr. Sem received his B.S. in Chemistry from UW-Milwaukee, his Ph.D. from UW-Madison in Biochemistry and his MBA and JD degrees from Marquette University.
Director, Research & Development
Curtis received his Bachelor's of Science in Chemistry from the University of Wisconsin-Milwaukee. He has been employed at the Bloodcenter of Wisconsin since 2012 in the laboratory of Anand Padmanabhan MD PhD. Curtis is a co-inventor of recent HIT diagnostic technology and author on numerous papers published in high impact journals on HIT diagnosis, treatment and pathogenesis. He is intimately familiar with the technical and scientific aspects of HITDx development.
Dr. Coutts is the Principal of Alembic Biotech Consultants, LLC, a firm specializing in services to both established and start-up biotechnology companies and to venture capital firms with a focus on the life science industry. Dr. Coutts has over 37 years’ experience in the pharmaceutical/biotech industry employing both small molecule and biologic approaches to drug development, as well as extensive immunoassay experience in two diagnostic companies. Most recently, he was Vice President of R&D at Alere San Diego, part of a $2.4 B global company. Before that, he was CEO of Biocept Laboratories, a company that analyzes genetic content in circulating tumor cells that are captured in a microfluidic device. Prior to that, Coutts spent one year as a Director of Pharmaceutical Development at Cypress Biosciences, which was preceded by his role as a Co-Founder of Triad Therapeutics where he was a member of its Board of Directors, as well as its President and COO, from 1998 to the end of 2004. From 1987 to 1998, Dr. Coutts was Executive Vice President for Research and Development at La Jolla Pharmaceutical Company (LJP), a biopharmaceutical company which he co-founded. At La Jolla Pharmaceutical he was responsible for establishing that company’s B cell Tolerance Technology™ platform and was an inventor of Riquent™ (LJP 394), a drug that ultimately failed phase 3 trials well after he left the company. Coutts was Executive Director of Drug Discovery for one year at Purdue Frederick, now Purdue Pharma. Prior to that, Dr. Coutts was at Revlon Health Care Group in Tuckahoe New York, for 11 years. As Department Director of Immunobiology he played a major role in the submission of four INDs for anti-allergic drug candidates. Dr. Coutts received his B.S. in Chemistry, with highest honors, at San Diego State University and a Ph.D. in Biochemistry with Frank Westheimer at Harvard University. He trained in biophysics as a postdoctoral fellow with Nobel Laureate Manfred Eigen in Germany, and was later a postdoctoral fellow and an instructor in Biochemistry at Princeton University. Dr. Coutts holds an M.B.A., with honors, from New York University.